Clinical Trial Opportunities
imuno® is 100+ times more potent than pure GcMAF
Superior Immune & Mitochondrial Support
- Rationale for the design of a novel tool for immunotherapy. Ruggiero M, Pacini S. Switzerland 27 Aug 2018, Integrative Cancer Science and Therapeutics, pages 1-5.
- A Novel potential Adjuvant for Cancer Vaccines. Ruggiero M, Pacini S. 29 Sept 2018, Madridge Journal of Vaccines, Vol. 2, pages 58-62.
- Clinical Experience of Integrative Autism treatment with a Novel type of Immunotherapy. Antonucci N, Pacini S, Ruggiero M. Italy 22 Feb 2019, Madridge Journal of Vaccines, Vol. 3, pages 71-76.
- Tailoring the Ruggiero-Klinghardt Protocol to Immunotherapy of Autism. Antonucci N, Klinghardt D, Pacini S, Ruggiero M. 24 Apr 2019, American Journal of Immunology, Vol. 14, pages 34-41.
- Use of an Extremely Biodiverse Probiotic and a Supplement Based on Microbial Chondroitin Sulfate is Associated with a Significant Decrease of Serum Free Kappa Light Chains as well as a Trend Toward Normalization of Kappa/Lambda Ratio and of Plasma Cell Bone Marrow Infiltration in a Case of Multiple Myeloma. Antonucci N, Pacini S, Ruggiero M. 18 Jun 2019, American Journal of Immunology, Vol. 15, pages 5-9.
- Color Doppler Evaluation of Isovolumetric Relaxation Time and of Signals Arising from Axons of the Median Nerve as a Means to Evaluate Mitochondrial Functionality in the Context of Immunotherapy of Cancer and Chronic Conditions Associated with Mitochondrial Dysfunction. Stefania Pacini and Marco Ruggiero. 12 Oct 2019, American Journal of Immunology.
- imuno® is over 100 times more effective than pure GcMAF. Marco Ruggiero. 19 Feb 2020, Public Letter.
- Consumption of an Extremely Biodiverse Probiotic and a Supplement based on Microbial Chondroitin Sulfate is Associated with Very Low Serum Alpha-N-acetylgalactosaminidase (Nagalase) Activity and Decrease of C-reactive Protein Values. Michael Carter, Stefania Pacini and Marco Ruggiero. 20 March 2020, American Journal of Immunology.
This website is accessible from many geographical locations, and the information that it provides regarding imuno® is not applicable to, nor intended to satisfy the requirements of all countries. imuno Corporation supplies imuno® to distributers throughout the world and does not make any claims regarding the use of these products and each distributor is responsible for ensuring that the claims made for and use of imuno® comply with the regulatory requirement of the locations in which it markets these products.
- GcMAF Made Better. (imuno® is 100+ times more potent than pure GcMAF)
- Superior Immune Support (BE WELL).
- Superior Endocannabinoid Receptor Support (FEEL WELL).
- Superior Mitochondrial Support (HAVE ENERGY).
- Superior Lymphatic Drainage Support (A BETTER FLOW).
imuno® is designed by Molecular Biologist, Dr Marco Ruggiero, MD. PhD. Author of peer-reviewed scientific papers on immunotherapy and quantum biology.
imuno® is produced under licence in a pharmaceutical facility which is audited by Medsafe, a division of the Ministry of Health of New Zealand, to both GMP and Pharmacy Standards NZ.
imuno® is the elegant solution. It is the revolutionary supra-molecular structure that reproduces the self-assembly of cell components. This delivers the combined molecules, at the same time, at the required dose, to their biologic targets, and produces powerful support. Also, the manufacturing process for imuno® is meticulous and time-consuming, and it is not technically possible to get the same result by simply mixing the active ingredients together since the procedure follows a proprietary algorithm based on biologic negentropy.
BioPlus Health Center
Unit A01-01, No.1, Harvard St,
Diamond Island, Tonle Basac, Chamkarmon,
Phnom Penh, Cambodia 12300.
Room 1410 Block B, No.18, Taolin Road,
Shanghai 200135, P.R.China.
Totech Japan Ltd.
1-2-5F United Asian, Tomiyama-cho,
Kanda, Chiyoda-ku, 101-0043 Japan.
Drakes Lane Industrial Estate,
Unit 1 Drakes Lane,
Boreham Essex CM3 3BE,
Click me to buy imuno online
Clinical Trial Opportunities